MedChemComm

英文简介

MedChemComm welcomes significant research and review articles in medicinal chemistry and related drug discovery science. We accept both communication and full paper style articles.Research articles published in MedChemComm must show a significant advance on previously published work, or bring new thinking or results which will potentially have a strong impact in their field.Examples of areas within the journal's scope are:Design, synthesis and biological evaluation of novel chemical or biochemical entities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.Modifications of known chemical or biochemical entities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or which provide other information of significant value, for example, the identification of a new target for a known agent. Routine modifications with minimal or no improvement are not suitable for MedChemComm.Note that studies where new or existing compounds are tested as pharmacological agents will only be considered if they are carried out in the presence of clear positive and negative controls and reference is made in the manuscript to the most powerful existing agents. Studies of this type should include a clearly defined and hypothesis-driven compound design rationale. Potential antimicrobial agents should be tested for cytotoxicity and activity against non-related pathogens.Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, structural biology, nanoscience) with application to drug discovery.Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies which report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or which has no demonstrated utility (or where the utility is unlikely to significantly advance the field) is not suitable for MedChemComm. Please note that docking studies presented without experimental data are not suitable for publication in the journal.Studies which examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.Note that studies which focus solely on drug delivery agents are not suitable for publication in MedChemComm.To help editors and referees assess the significance of each submitted manuscript we ask all authors on submission to provide a brief statement of significance. This should contain one sentence to summarise the most important finding(s) in the manuscript and a second sentence to say why this is a significant advance in the field. This significance statement should focus specifically on the importance of the piece of research being submitted, rather than the importance of the field.

中文简介

医学化学通讯欢迎在药物化学和相关药物发现科学方面的重要研究和评论文章。我们接受通讯和全纸风格的文章。在医学化学通讯上发表的研究论文必须比以前发表的论文有显著的进步，或者带来新的想法或结果，这些想法或结果可能会对他们的领域产生强大的影响。期刊范围内的领域包括：新型化学或生化实体的设计、合成和生物评价。为了适合发表，这些必须表现出显着的潜力，作为新的药物制剂，工具，探针或潜在的药物。对已知化学或生物化学实体的修改，可使对它们的结构-活性关系有更大的了解，改善它们的性质或提供其他有重要价值的信息，例如，为已知的试剂确定新目标。常规的修改很少或没有改进，不适合医学通讯。注意，只有在明确的阳性对照和阴性对照的情况下进行新化合物或现有化合物作为药理学试剂进行测试的研究，并在原稿中参考现有最有效的药剂，才会考虑这些研究。这种类型的研究应该包括一个明确定义和假设驱动的复合设计理论。潜在的抗菌药物应进行细胞毒性和对非相关病原体的活性测试。在更广泛的化学和生物科学(例如，使合成化学，化学生物学，组学科学，结构生物学，纳米科学)的新方法和技术应用于药物发现。计算研究是受欢迎的，因为它们大大提高了药物化学知识。使用已建立的计算方法进行的研究应包括原始预测，并应附以新的实验数据，以验证所作的预测。报道新的计算方法的研究必须通过与实验数据的比较来证明其在药物化学中的应用。不清楚地将所得结果与实验数据联系起来的计算研究，或者没有显示出实用价值的计算研究(或者实用价值不太可能显著促进该领域的发展)，不适合医学化学通讯。请注意，没有实验数据的对接研究不适合发表在杂志上。研究化合物的分子结构对药物动力学行为和药效学的影响。请注意，只专注于药物传递剂的研究不适合在医学化学通讯发表。为了帮助编辑和审稿人评估每一篇投稿的重要性，我们要求所有投稿作者在投稿时提供一份简要的重要性陈述。这应该包括一句话来总结手稿中最重要的发现，第二句话来说明为什么这是该领域的重大进展。这一重要性声明应具体侧重于所提交研究报告的重要性，而不是该领域的重要性。

影响因子趋势图